SCHEMBL5778752

SCHEMBL5778752

Cc1ccc(S(=O)(=O)N2CCN(c3ccc(C(F)(F)F)cn3)C(C)C2C)cc1CC(=O)O

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 5/20 0.40
NR1H3 Q13133 5/20 0.40
GPR119 Q8TDV5 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
HPGD P15428 1/20 0.38
GCKR Q14397 3/20 0.38
KDM4E B2RXH2 2/20 0.38
AGBL2 Q5U5Z8 1/20 0.38
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
PPARG P37231 1/20 0.37
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37
CXCR3 P49682 3/20 0.37
MAPT P10636 1/20 0.37
CNR2 P34972 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6348217 0.86 CXCR3 (0.46) NR1H2NR1H3KDM4EAGBL2CXCR3
SCHEMBL6356889 0.85 CXCR3 (0.48) NR1H2NR1H3GCKRKDM4ECXCR3
SCHEMBL6357386 0.85 CXCR3 (0.48) NR1H2NR1H3GCKRKDM4ECXCR3
SCHEMBL5480564 0.85 CXCR3 (0.48) NR1H2NR1H3GCKRKDM4ECXCR3
SCHEMBL5747494 0.85 CXCR3 (0.47) GPR119SMN1; SMN2HPGDKDM4ELMNA
SCHEMBL1471200 0.85 NR1H2 (0.38) NR1H2NR1H3GPR119PPARGPPARD
SCHEMBL12749864 0.85 NR1H2 (0.38) NR1H2NR1H3GPR119PPARGPPARD
SCHEMBL5746016 0.85 NR1H2 (0.46) NR1H2NR1H3GPR119HPGD
SCHEMBL5768967 0.85 PPARG (0.41) NR1H2NR1H3GPR119SMN1; SMN2HPGD
SCHEMBL27734620 0.84 SMN1; SMN2 (0.43) GPR119SMN1; SMN2HPGDKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD NR1H2 19/4885NR1H3 29/4885GPR119 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.